Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M886Revenue (TTM) $M6.9Net Margin (%)-2,409.2Altman Z-Score-10.2
Enterprise Value $M805EPS (TTM) $-1.3Operating Margin %-2,409.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score-7.3Pre-tax Margin (%)-2,409.2Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-3.9Quick Ratio6.6Cash flow > EarningsY
Price/Sales1295-y EBITDA Growth Rate %-1.6Current Ratio6.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-127.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M132ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ZIOP

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ZIOP is held by these investors:

ZIOP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELBEL CAESAR JCOO, CLO, and Secretary 2015-11-19Sell153,333$12.84-47.9view
LEBEL FRANCOISExecutive Vice President R&D 2015-06-09Sell50,000$10.12-33.89view
BRENNAN MURRAYDirector 2015-06-04Sell40,000$9.7-31.03view
Lafond Kevin GVice Pres., Treasurer, & CAO 2015-06-03Sell57,500$9.65-30.67view
KIRK RANDAL JDirector, 10% Owner 2015-02-09Buy1,440,000$8.75-23.54view
KIRK RANDAL JDirector, 10% Owner 2013-10-29Buy2,857,143$3.591.14view
KIRK RANDAL JDirector, 10% Owner 2012-01-20Buy1,923,075$5.228.65view
KIRK RANDAL JDirector, 10% Owner 2011-08-23Buy38,294$4.9934.07view
KIRK RANDAL JDirector, 10% Owner 2011-08-22Buy461,646$4.9235.98view
Fowler WycheDirector 2011-08-10Buy5,000$5.1928.9view

Press Releases about ZIOP :

Quarterly/Annual Reports about ZIOP:

News about ZIOP:

Articles On GuruFocus.com
Intrexon Corp is expanding his business Jun 25 2015 
Hayman Advisors Update - Second Quarter Sells and Company Results Aug 26 2013 
Bass’ New Buy – ZIOPHARM Oncology Inc. May 16 2013 
The Far-Off Four, 52-week Lows Held by Gurus May 11 2013 

More From Other Websites
Catalyst Pharmaceuticals and ZIOPHARM Oncology Bounce Up On FDA Phase News Mar 28 2017
FDA Allows Ziopharm's Brain Cancer Drug Trial Mar 27 2017
ZIOPHARM ONCOLOGY INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 27 2017
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in... Mar 27 2017
ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications Mar 27 2017
ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : March 21,... Mar 21 2017
Don't Overlook Ziopharm Oncology Mar 20 2017
Implied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options Mar 20 2017
Biotechs Among 5 Stocks Setting Up for Major Breakouts Mar 12 2017
Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
ZIOPHARM ONCOLOGY INC Financials Feb 22 2017
ZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Feb 22 2017
Ziopharm 4Q Loss 11 Cents a Share Vs 7c Last Year Feb 17 2017
Ziopharm reports 4Q loss Feb 16 2017
Ziopharm reports 4Q loss Feb 16 2017
ZIOPHARM ONCOLOGY INC Files SEC form 10-K, Annual Report Feb 16 2017
ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities Feb 16 2017
6 Hot Stocks Among Shorts: IBM, Exxon Mobil And More Jan 31 2017
ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells... Jan 31 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)